Search This Blog

Wednesday, September 23, 2026

Gossamer Bio submits first NDA to U.S. FDA for seralutinib to treat pulmonary arterial hypertension

 


  • Submission is supported by data from the Phase 3 PROSERA trial and Phase 2 TORREY trial.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)